3D Printing MicroFactory for Amorphous Solid Dispersion formulations
![3D Printing MicroFactory for Amorphous Solid Dispersion formulations](https://www.pharmaexcipients.com/wp-content/uploads/2024/07/3D-Printing-MicroFactory-for-Amorphous-Solid-Dispersion-formulations.png)
The Poster was presented at CMAC Summer School 2024
Context and Aim of Work
This study utilised the HUB Additive-ManufacturingMicroFactory as an enabler for streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® as a superior polymer to form stable ASD formulation with Ritonavir.
The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).
Conclusion
A novel integrated HME-3D printer, the HUB ‘Additive-Manufacturing-MicroFactory’ enabled streamlined manufacture and performance testing of ASD formulation consisting of Ritonavir in Soluplus® polymer. By altering the porosity of the tablet core through additive manufacturing, product performance equivalent to a commercial product was obtained.
Download the full study as PDF here:
3D Printing MicroFactory for Amorphous Solid Dispersion formulations
or read it here
Prasad, E., Hueckman, J., Bordos, E., Robertson, J., & Halbert, G. W. (2024). 3D printing MicroFactory for amorphous solid dispersion formulations. Poster session presented at CMAC Summer School 2024, Dunblane, United Kingdom.